KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Taxes: 2020-2022

Historic Current Taxes for AbCellera Biologics (ABCL) over the last 2 years, with Sep 2022 value amounting to $23.0 million.

  • AbCellera Biologics' Current Taxes rose 249.29% to $23.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $23.0 million, marking a year-over-year increase of 249.29%. This contributed to the annual value of $35.7 million for FY2021, which is 1.30% down from last year.
  • Latest data reveals that AbCellera Biologics reported Current Taxes of $23.0 million as of Q3 2022, which was down 78.55% from $107.3 million recorded in Q2 2022.
  • Over the past 5 years, AbCellera Biologics' Current Taxes peaked at $107.3 million during Q2 2022, and registered a low of $5.8 million during Q2 2021.
  • Over the past 3 years, AbCellera Biologics' median Current Taxes value was $32.9 million (recorded in 2021), while the average stood at $43.8 million.
  • In the last 5 years, AbCellera Biologics' Current Taxes dropped by 1.30% in 2021 and then spiked by 1,743.39% in 2022.
  • AbCellera Biologics' Current Taxes (Quarterly) stood at $36.2 million in 2020, then declined by 1.30% to $35.7 million in 2021, then spiked by 249.29% to $23.0 million in 2022.
  • Its Current Taxes was $23.0 million in Q3 2022, compared to $107.3 million in Q2 2022 and $105.6 million in Q1 2022.